Converting Tumoral PD-L1 into a 4-1BB Agonist for Safer and More Effective Cancer Immunotherapy

被引：4

作者：

Li, Zihai ^{[1
,2
]}

Azar, Joseph H. ^{[1
,2
]}

Rubinstein, Mark P. ^{[1
,2
]}

机构：

[1] Ohio State Univ, Div Med Oncol, Dept Internal Med, Columbus, OH USA

[2] Ohio State Univ, James Comprehens Canc Ctr, Plotonia Inst Immunooncol, 460 W 12th Ave,BRT 510,Biomed Res Tower, Columbus, OH 43210 USA

来源：

CANCER DISCOVERY | 2022年 / 12卷 / 05期

关键词：

D O I：

10.1158/2159-8290.CD-22-0219

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Dose-limiting toxicities are thought to temper the efficacy of single-agent 4-1BB agonists. To overcome this hurdle, in this issue of Cancer Discovery, Muik and colleagues report preclinical and clinical studies describing a first-in-class bispecific fusion protein targeting 4-1BB and PD-L1.

引用

页码：1184 / 1186

页数：3

共 50 条

[41] PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity
Hosseinzadeh, Ramin
Feizisani, Fahimeh
Shomali, Navid
Abdelbasset, Walid Kamal
Hemmatzadeh, Maryam
Gholizadeh Navashenaq, Jamshid
Jadidi-Niaragh, Farhad
Bokov, Dmitry O.
Janebifam, Morteza
Mohammadi, Hamed
IUBMB LIFE, 2021, 73 (11) : 1293 - 1306
[42] Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
François Bertucci
Anthony Gonçalves
Current Oncology Reports, 2017, 19
[43] Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
Chardin, Laure
Leary, Alexandra
FRONTIERS IN ONCOLOGY, 2021, 11
[44] The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer
Xu, Yichi
Song, Gendi
Xie, Shangdan
Jiang, Wenxiao
Chen, Xin
Chu, Man
Hu, Xiaoli
Wang, Zhi-Wei
MOLECULAR THERAPY, 2021, 29 (06) : 1958 - 1969
[45] Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy
Li, Chunlin
Zhang, Nengpan
Zhou, Jundong
Ding, Chen
Jin, Yaqing
Cui, Xueyuan
Pu, Kefeng
Zhu, Yimin
CANCER IMMUNOLOGY RESEARCH, 2018, 6 (02) : 178 - 188
[46] Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma
Zheng, Zhong
Wang, Jian-Biao
Sun, Rui
Wang, Nan
Weng, Xiang-Qin
Xu, Tian-Yuan
Fu, Di
Feng, Yan
Xu, Peng-Peng
Cheng, Shu
Wang, Li
Zhao, Yan
Qu, Bin
Huang, Chuan-Xin
Zhao, Wei-Li
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
[47] ATG-101, A NOVEL PD-L1/4-1BB BISPECIFIC ANTIBODY, AUGMENTS ANTI-TUMOR IMMUNITY THROUGH IMMUNE CHECKPOINT INHIBITION AND PDL1-DIRECTED 4-1BB ACTIVATION
Hui Yuwen
Li, Tengteng
Ren, Yijing
Hoenemann, Dirk
Mei, Jay
Shan, Bo
Hou, Bing
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A936 - A937
[48] GEN1046 (Bispecific Antibody Targeting PD-L1 and 4-1BB): Preclinical Characteristics and Phase 1 Results in Solid Tumors
Kunkel, Maria
Muik, Alexander
Altintas, Isil
Gieseke, Friederike
Schodel, Kristina
Diken, Mustafa
Sette, Angelica
Stanganello, Eliana
Vascotto, Fulvia
Breij, Esther
Sasser, Kate
Tureci, Ozlem
Forssmann, Ulf
Ahmadi, Tahamtan
Sahin, Ugur
CANCER SCIENCE, 2023, 114 : 1566 - 1566
[49] Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy
Zhang, Jinfang
Dang, Fabin
Ren, Junming
Wei, Wenyi
TRENDS IN BIOCHEMICAL SCIENCES, 2018, 43 (12) : 1014 - 1032
[50] Beyond PD-L1 Markers for Lung Cancer Immunotherapy
Wojas-Krawczyk, Kamila
Kalinka, Ewa
Grenda, Anna
Krawczyk, Pawel
Milanowski, Janusz
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (08)

← 1 2 3 4 5 →